B
Novo Nordisk A/S NVO
$124.23 $4.463.72%
Recommendation
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
52-Week Range
P/E (TTM)
EPS (TTM)
B
Buy 2/13/2024Downgrade
Novo Nordisk A/S (NVO) was downgraded to B from B+ on 2/13/2024 due to a noticeable decline in the growth index, total return index and valuation index. Operating cash flow declined 76.95% from $5.98B to $1.38B, and earnings per share declined from $0.7302 to $0.7086.
B
Buy 11/3/2023Upgraded
Novo Nordisk A/S (NVO) was upgraded to B+ from B on 11/3/2023 due to a large increase in the total return index, volatility index and growth index. Operating cash flow increased 43.28% from $4.18B to $5.98B, earnings per share increased from $0.6305 to $0.7302, and EBIT increased 12.61% from $3.49B to $3.93B.
B
Buy 9/19/2023Upgraded
Novo Nordisk A/S (NVO) was upgraded to B from C+ on 9/19/2023 due to a major increase in the valuation index and dividend index.
C
Hold 9/14/2023Downgrade
Novo Nordisk A/S (NVO) was downgraded to C+ from B- on 9/14/2023 due to a large decline in the total return index.
B
Buy 9/12/2023Downgrade
Novo Nordisk A/S (NVO) was downgraded to B- from B on 9/12/2023 due to a major decline in the valuation index and total return index.
B
Buy 1/4/2023Downgrade
Novo Nordisk A/S (NVO) was downgraded to B from B+ on 1/4/2023 due to a decline in the total return index and valuation index.
B
Buy 12/20/2022Upgraded
Novo Nordisk A/S (NVO) was upgraded to B+ from B on 12/20/2022 due to a significant increase in the total return index and volatility index.
B
Buy 10/17/2022Downgrade
Novo Nordisk A/S (NVO) was downgraded to B from B+ on 10/17/2022 due to a decline in the volatility index, valuation index and dividend index.
B
Buy 9/30/2022Upgraded
Novo Nordisk A/S (NVO) was upgraded to B+ from B on 9/30/2022 due to an increase in the valuation index and dividend index.
B
Buy 8/9/2022Downgrade
Novo Nordisk A/S (NVO) was downgraded to B from B+ on 8/9/2022 due to a major decline in the total return index.
B
Buy 8/5/2022Downgrade
Novo Nordisk A/S (NVO) was downgraded to B+ from A- on 8/5/2022 due to a decline in the total return index, dividend index and valuation index.
A
Buy 8/4/2022Upgraded
Novo Nordisk A/S (NVO) was upgraded to A- from B+ on 8/4/2022 due to a large increase in the total return index.
B
Buy 7/7/2022Downgrade
Novo Nordisk A/S (NVO) was downgraded to B+ from A- on 7/7/2022 due to a large decline in the total return index, valuation index and dividend index.
A
Buy 6/22/2022Upgraded
Novo Nordisk A/S (NVO) was upgraded to A- from B+ on 6/22/2022 due to a noticeable increase in the total return index.
B
Buy 6/2/2022Downgrade
Novo Nordisk A/S (NVO) was downgraded to B+ from A- on 6/2/2022 due to a noticeable decline in the total return index.
A
Buy 5/16/2022Upgraded
Novo Nordisk A/S (NVO) was upgraded to A- from B on 5/16/2022 due to a substantial increase in the total return index, valuation index and dividend index.
B
Buy 5/3/2022Downgrade
Novo Nordisk A/S (NVO) was downgraded to B from B+ on 5/3/2022 due to a decline in the growth index and valuation index. Operating cash flow declined 113.61% from $3.41B to -$464.02M, earnings per share declined from $0.8352 to $0.7326, and EBIT declined 8.79% from $2.42B to $2.2B.
B
Buy 5/2/2022Upgraded
Novo Nordisk A/S (NVO) was upgraded to B+ from B on 5/2/2022 due to a large increase in the total return index and growth index. Operating cash flow increased 866.01% from -$464.02M to $3.55B, EBIT increased 30.91% from $2.2B to $2.89B, and total revenue increased 7.44% from $5.9B to $6.33B.
B
Buy 3/25/2022Downgrade
Novo Nordisk A/S (NVO) was downgraded to B from B+ on 3/25/2022 due to a decline in the volatility index, valuation index and total return index.
B
Buy 2/3/2022Upgraded
Novo Nordisk A/S (NVO) was upgraded to B+ from B on 2/3/2022 due to a noticeable increase in the valuation index and solvency index.
B
Buy 1/13/2022Downgrade
Novo Nordisk A/S (NVO) was downgraded to B from B+ on 1/13/2022 due to a noticeable decline in the total return index and volatility index.
B
Buy 1/12/2022Downgrade
Novo Nordisk A/S (NVO) was downgraded to B+ from A- on 1/12/2022 due to a noticeable decline in the total return index.
A
Buy 11/8/2021Upgraded
Novo Nordisk A/S (NVO) was upgraded to A- from B+ on 11/8/2021 due to an increase in the growth index, volatility index and total return index. Total revenue increased 5.42% from $5.36B to $5.65B, and EBIT increased 0.89% from $2.4B to $2.42B.
B
Buy 10/22/2021Downgrade
Novo Nordisk A/S (NVO) was downgraded to B+ from A- on 10/22/2021 due to a decline in the valuation index and dividend index.
A
Buy 10/1/2021Upgraded
Novo Nordisk A/S (NVO) was upgraded to A- from B+ on 10/1/2021 due to an increase in the valuation index, total return index and volatility index.
B
Buy 9/2/2021Upgraded
Novo Nordisk A/S (NVO) was upgraded to B+ from B on 9/2/2021 due to a major increase in the total return index and volatility index.
B
Buy 8/18/2021Downgrade
Novo Nordisk A/S (NVO) was downgraded to B from A- on 8/18/2021 due to a noticeable decline in the total return index, valuation index and dividend index.
A
Buy 8/6/2021Upgraded
Novo Nordisk A/S (NVO) was upgraded to A- from B on 8/6/2021 due to a large increase in the total return index, growth index and valuation index. Operating cash flow increased 124.44% from $1.82B to $4.09B.
B
Buy 7/15/2021Downgrade
Novo Nordisk A/S (NVO) was downgraded to B from B+ on 7/15/2021 due to a decline in the valuation index and dividend index.
B
Buy 6/28/2021Downgrade
Novo Nordisk A/S (NVO) was downgraded to B+ from A- on 6/28/2021 due to a decline in the total return index and valuation index.
A
Buy 6/11/2021Upgraded
Novo Nordisk A/S (NVO) was upgraded to A- from B+ on 6/11/2021 due to a noticeable increase in the total return index and volatility index.
B
Buy 5/7/2021Upgraded
Novo Nordisk A/S (NVO) was upgraded to B+ from B on 5/7/2021 due to a large increase in the volatility index, dividend index and total return index.
B
Buy 2/19/2021Upgraded
Novo Nordisk A/S (NVO) was upgraded to B from B- on 2/19/2021 due to an increase in the volatility index.
B
Buy 2/4/2021Downgrade
Novo Nordisk A/S (NVO) was downgraded to B- from B on 2/4/2021 due to a decline in the growth index, solvency index and total return index. Debt to equity increased from 0.02 to 0.16, operating cash flow declined 99% from $2.75B to $27.54M, and the quick ratio declined from 0.76 to 0.64.
B
Buy 2/1/2021Upgraded
Novo Nordisk A/S (NVO) was upgraded to B from B- on 2/1/2021 due to an increase in the total return index and volatility index.
B
Buy 1/8/2021Downgrade
Novo Nordisk A/S (NVO) was downgraded to B- from B on 1/8/2021 due to a large decline in the total return index, dividend index and volatility index.
B
Buy 2/24/2020Upgraded
Novo Nordisk A/S (NVO) was upgraded to B from C+ on 2/24/2020 due to a large increase in the total return index, dividend index and volatility index.
C
Hold 2/12/2020Downgrade
Novo Nordisk A/S (NVO) was downgraded to C+ from B- on 2/12/2020 due to a major decline in the growth index, valuation index and volatility index. Operating cash flow declined 69.22% from $2.49B to $765.5M, earnings per share declined from $0.6393 to $0.5478, and EBIT declined 8.59% from $1.93B to $1.76B.
B
Buy 11/27/2019Downgrade
Novo Nordisk A/S (NVO) was downgraded to B- from B on 11/27/2019 due to a decline in the volatility index and valuation index.
B
Buy 11/7/2019Upgraded
Novo Nordisk A/S (NVO) was upgraded to B from B- on 11/7/2019 due to a noticeable increase in the growth index, volatility index and total return index. Operating cash flow increased 9.87% from $2.26B to $2.49B, and earnings per share increased from $0.6065 to $0.6393.
B
Buy 9/3/2019Upgraded
Novo Nordisk A/S (NVO) was upgraded to B- from C+ on 9/3/2019 due to an increase in the dividend index, volatility index and total return index.
C
Hold 5/22/2019Upgraded
Novo Nordisk A/S (NVO) was upgraded to C+ from C on 5/22/2019 due to an increase in the volatility index and valuation index.
C
Hold 5/7/2019Downgrade
Novo Nordisk A/S (NVO) was downgraded to C from C+ on 5/7/2019 due to a decline in the dividend index, solvency index and valuation index. Debt to equity increased from 0.01 to 0.09, and the quick ratio declined from 0.79 to 0.65.
C
Hold 2/25/2019Upgraded
Novo Nordisk A/S (NVO) was upgraded to C+ from C on 2/25/2019 due to an increase in the dividend index, total return index and growth index. Total revenue increased 5.03% from $4.33B to $4.55B.
C
Hold 11/6/2018Downgrade
Novo Nordisk A/S (NVO) was downgraded to C from C+ on 11/6/2018 due to a decline in the growth index, total return index and dividend index. Operating cash flow declined 28.22% from $2.53B to $1.81B, earnings per share declined from $0.6821 to $0.5834, and EBIT declined 5.7% from $1.95B to $1.84B.
C
Hold 10/19/2018Upgraded
Novo Nordisk A/S (NVO) was upgraded to C+ from C on 10/19/2018 due to an increase in the total return index, valuation index and dividend index.
C
Hold 10/4/2018Downgrade
Novo Nordisk A/S (NVO) was downgraded to C from C+ on 10/4/2018 due to a decline in the volatility index.
C
Hold 9/6/2018Upgraded
Novo Nordisk A/S (NVO) was upgraded to C+ from C on 9/6/2018 due to a noticeable increase in the growth index, volatility index and valuation index. Operating cash flow increased 55.87% from $1.62B to $2.53B.
C
Hold 4/2/2018Downgrade
Novo Nordisk A/S (NVO) was downgraded to C from C+ on 4/2/2018 due to a substantial decline in the growth index, volatility index and solvency index. Debt to equity increased from 0.01 to 0.03, operating cash flow declined 53.26% from $2.04B to $954.29M, and earnings per share declined from $0.6258 to $0.5314.
C
Hold 10/23/2017Upgraded
Novo Nordisk A/S (NVO) was upgraded to C+ from C on 10/23/2017 due to an increase in the total return index, volatility index and dividend index.
C
Hold 6/1/2017Upgraded
Novo Nordisk A/S (NVO) was upgraded to C from C- on 6/1/2017 due to an increase in the volatility index, growth index and total return index. Earnings per share increased from $0.5017 to $0.582, EBIT increased 14.68% from $1.69B to $1.93B, and operating cash flow increased 7.17% from $1.62B to $1.73B.
C
Hold 2/10/2017Upgraded
Novo Nordisk A/S (NVO) was upgraded to C- from D+ on 2/10/2017 due to an increase in the dividend index, growth index and valuation index. Total revenue increased 3.82% from $4.13B to $4.29B.
D
Sell 1/26/2017Downgrade
Novo Nordisk A/S (NVO) was downgraded to D+ from C- on 1/26/2017 due to a decline in the total return index, valuation index and volatility index.
C
Hold 12/1/2016Downgrade
Novo Nordisk A/S (NVO) was downgraded to C- from C on 12/1/2016 due to a noticeable decline in the volatility index, growth index and total return index. Earnings per share declined from $0.5952 to $0.5804, EBIT declined 1.83% from $1.9B to $1.86B, and total revenue declined 0.94% from $4.17B to $4.13B.
C
Hold 10/12/2016Downgrade
Novo Nordisk A/S (NVO) was downgraded to C from C+ on 10/12/2016 due to a decline in the volatility index and total return index.
C
Hold 9/13/2016Downgrade
Novo Nordisk A/S (NVO) was downgraded to C+ from B- on 9/13/2016 due to a decline in the volatility index and total return index.
B
Buy 8/19/2016Downgrade
Novo Nordisk A/S (NVO) was downgraded to B- from B on 8/19/2016 due to a large decline in the total return index, volatility index and dividend index.
B
Buy 3/14/2016Downgrade
Novo Nordisk A/S (NVO) was downgraded to B from A- on 3/14/2016 due to a decline in the volatility index and valuation index.
A
Buy 3/1/2016Upgraded
Novo Nordisk A/S (NVO) was upgraded to A- from B+ on 3/1/2016 due to an increase in the volatility index and total return index.
B
Buy 2/22/2016Upgraded
Novo Nordisk A/S (NVO) was upgraded to B+ from B on 2/22/2016 due to an increase in the valuation index, dividend index and solvency index. The quick ratio increased from 0.99 to 1.03.
B
Buy 12/31/2015Downgrade
Novo Nordisk A/S (NVO) was downgraded to B from B+ on 12/31/2015 due to a noticeable decline in the volatility index, total return index and growth index. EBIT declined 3.57% from $1.85B to $1.79B, and total revenue declined 0.52% from $4.01B to $3.99B.
B
Buy 9/21/2015Downgrade
Novo Nordisk A/S (NVO) was downgraded to B+ from A- on 9/21/2015 due to a large decline in the total return index, volatility index and growth index. Earnings per share declined from $0.5722 to $0.4791.
A
Buy 5/1/2015Downgrade
Novo Nordisk A/S (NVO) was downgraded to A- from A on 5/1/2015 due to a decline in the dividend index and solvency index. The quick ratio declined from 1 to 0.74.
A
Buy 4/21/2015Upgraded
Novo Nordisk A/S (NVO) was upgraded to A from A- on 4/21/2015 due to a significant increase in the volatility index and total return index.
A
Buy 2/6/2015Upgraded
Novo Nordisk A/S (NVO) was upgraded to A- from B+ on 2/6/2015 due to an increase in the dividend index.
B
Buy 1/27/2015Upgraded
Novo Nordisk A/S (NVO) was upgraded to B+ from B on 1/27/2015 due to an increase in the volatility index.
B
Buy 12/23/2014Downgrade
Novo Nordisk A/S (NVO) was downgraded to B from B+ on 12/23/2014 due to a major decline in the volatility index, growth index and solvency index. Earnings per share declined from $0.4888 to $0.4392, and total revenue declined 0.47% from $3.97B to $3.96B.
B
Buy 10/14/2014Downgrade
Novo Nordisk A/S (NVO) was downgraded to B+ from A- on 10/14/2014 due to a decline in the total return index and valuation index.
A
Buy 8/29/2014Upgraded
Novo Nordisk A/S (NVO) was upgraded to A- from B+ on 8/29/2014 due to a noticeable increase in the growth index and solvency index. Operating cash flow increased 99.81% from $747.3M to $1.49B, debt to equity declined from 0.02 to 0.01, and the quick ratio increased from 0.88 to 0.98.
B
Buy 5/5/2014Downgrade
Novo Nordisk A/S (NVO) was downgraded to B+ from A on 5/5/2014 due to a decline in the solvency index, dividend index and valuation index. The quick ratio declined from 1.23 to 0.88.
Weiss Ratings